Journal
FEBS JOURNAL
Volume 287, Issue 12, Pages 2418-2427Publisher
WILEY
DOI: 10.1111/febs.15264
Keywords
dasatinib; fisetin; Geroscience Hypothesis; MAD cells; navitoclax; quercetin; SASP; SCAPs; senolytics
Categories
Funding
- NIA NIH HHS [R56 AG061414, P01 AG062413, R37 AG013925, R33 AG061456] Funding Source: Medline
Ask authors/readers for more resources
Senescent cells accumulate with aging and at etiological sites of multiple diseases, including those accounting for most morbidity, mortality, and health costs. Senescent cells do not replicate, can release factors that cause tissue dysfunction, and yet remain viable. The discovery of senolytic drugs, agents that selectively eliminate senescent cells, created a new route for alleviating age-related dysfunction and diseases. As anticipated for agents targeting fundamental aging mechanisms that are 'root cause' contributors to multiple disorders, potential applications of senolytics are protean. We review the discovery of senolytics, strategies for translation into clinical application, and promising early signals from clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available